Kurser indlæses...
Prognose
| Køb |
13 |
| Behold |
2 |
| Sælg |
1 |
Diskussioner i communityet
Der er endnu ingen diskussion om dette aktiv.
Start diskussionNyheder Til nyhedsfeedet
Cellectis reports quarterly loss per share of $0.26 and declining revenue
Cellectis reported earnings per share of -$0.26 for the most recent quarter, after -$0.080 in the year-ago quarter. Quarterly revenue fell to $10.4 million (-17.74% versus $12.6 million). For the full year, the company shows a loss per share of -$0.670, while annual revenue rose sharply to $73.17 million (±76.61% versus $41.43 million). » Mere på finanzen.net
Cellectis beats Q4 2025 revenue and EPS forecasts, stock rises
Cellectis reported Q4 2025 EPS of -$0.19 (forecast -$0.2948) and revenue of $17.1 million (forecast $10.02 million), both well above expectations. The stock rose 2.01% in premarket trading to $3.55. Cash resources of $211 million secure the company’s financial runway into the second half of 2027. The company highlights progress on the Lasme‑Cel and Eti‑Cel programmes and the validation of internal manufacturing capacities. » Mere på de.investing.com
Cellectis: arbitration panel partially terminates license agreement with Servier
An arbitration panel has partially terminated the 2019 license, development and commercialization agreement between Cellectis and Servier. The decision specifically concerns the product UCART19 V1 (also ALLO-501) and obliges Cellectis, upon request, to enter into good-faith negotiations with Allogene regarding a direct licensing arrangement. All other claims brought in the arbitration were dismissed. » Mere på de.investing.com
Cellectis achieves breakthrough in non-viral gene insertion method
Cellectis and Moligo present in Nature Communications a non-viral gene insertion method for hematopoietic stem and progenitor cells (HSPCs) based on enzymatically produced circular single-stranded DNA (CssDNA). The circular ssDNA format reached insertion rates above 40% and was 3- to 5-fold more efficient than linear ssDNA; in mouse models, CssDNA-edited HSPCs showed better expansion and retention of edits than with AAV6. The collaboration aims to provide a scalable alternative to viral vectors and strengthen Cellectis' position in gene editing, while analysts see a price target of $7.50 and the company, despite strong revenue growth, is not yet profitable. » Mere på de.investing.com
Cellectis reports strong phase‑1 data for leukemia therapy lasme‑cel
Cellectis released promising phase‑1 data from the BALLI‑01 study of lasme‑cel (UCART22) in relapsed/refractory B‑ALL: overall response rate 68% (manufacturing process 2), 83% at the dose recommended for phase‑2 and 100% in the phase‑2 target population. In that target group, 56% achieved complete remission (CR/CRi) and about 80% were minimal residual disease (MRD) negative; 78% of patients eligible for transplant received one. The therapy showed activity even in heavily pretreated patients and was generally well tolerated. Cellectis has initiated a registration‑enabling phase‑2 study (first patient expected Q4 2025) and is targeting a BLA submission in 2028; Q2 financials showed mixed signals with revenue above forecast but an EPS miss. » Mere på de.investing.com
Virksomhedstal
| (EUR) | september 2026 | YoY |
|---|---|---|
| Omsætning | 3,76 mio. | 89,30 % |
| Bruttofortjeneste | 1,27 mio. | 96,13 % |
| Nettoresultat | -61,47 mio. | 10.537,01 % |
| EBITDA | -27,79 mio. | 460,63 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 71,53 mio. € |
Antal aktier | 72,33 mio. |
Højeste/laveste i 52 uger | 4,75 € - 0,90 € |
| Udbytte | Nej |
Beta | 2,91 |
P/E (PE Ratio) | -0,85 |
PEG (PEG Ratio) | 0,01 |
K/I (PB Ratio) | -6,20 |
P/S (PS Ratio) | 3,12 |
Virksomhedsprofil
Cellectis S.A. er et klinisk udviklet bioteknologisk selskab, der udvikler immunonkologiske produkter baseret på genredigerede T-celler, som udtrykker kimære antigenreceptorer for at målrette og udrydde kræftceller. Virksomheden er organiseret i to segmenter, Therapeutics og Plants. Selskabet udvikler UCART19, et allogent T-celle-produktkandidat til behandling af CD19-udtrykkende hæmatologiske maligniteter, såsom akut lymfoblastisk leukæmi; ALLO-501 og ALLO-501A til behandling af recidiverende/refraktær diffus storcellet B-celle-lymfom og follikulær lymfom; ALLO-316 til behandling af nyrecellekarcinom; UCART123 til behandling af akut myeloid leukæmi; og UCART22 til behandling af B-celle akut lymfoblastisk leukæmi. Selskabet udvikler også UCARTCS1 og ALLO-715 til behandling af multipel myelom. Virksomheden har strategiske alliancer med Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; og Iovance Biotherapeutics samt et strategisk forsknings- og udviklingssamarbejde med Cytovia Therapeutics, Inc. Cellectis S.A. blev grundlagt i 1999 og har hovedkontor i Paris, Frankrig.
| Navn | Cellectis |
| CEO | Andre Choulika |
| Hjemsted | Paris,
if Frankrig |
| Websted | |
| Børsnotering | 07.02.2007 |
| Medarbejdere | 227 |
Deep Dive
Tickersymboler
| Børs | Symbol |
|---|---|
Euronext | ALCLS.PA |
Pnk | CMVLF |
Frankfurt | ZVA.F |
Düsseldorf | ZVA.DU |
London | 0WA2.L |
Paris | ALCLS.PA |
München | ZVA.MU |